Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
This article was originally published in The Gray Sheet
Executive Summary
Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.
You may also be interested in...
GERD Device Efficacy Data Deemed Unconvincing By AGA Consensus Panel
The American Gastroenterological Assocation advises against using medical devices in lieu of pharmacological management to treat endoscopic gastroesophageal reflux disease (GERD) in a November consensus development report
GERD Device Efficacy Data Deemed Unconvincing By AGA Consensus Panel
The American Gastroenterological Assocation advises against using medical devices in lieu of pharmacological management to treat endoscopic gastroesophageal reflux disease (GERD) in a November consensus development report
Curon Secca Incontinence System One-Year Data Include 80% Success Rate
One-year follow-up data on ten patients treated with Curon Medical's Secca radiofrequency system for treatment of fecal incontinence, slated for release in June, include an 80% success rate, Curon says.